Asset
RIBAXAMASE
Theriva Biologics Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02473640 | phase1_2 | completed | 2015-06-01 | 2016-04-01 | Theriva Biologics, Inc. | A Study Evaluating the Effect of Esomeprazole on SYN-004 Degradation of Ceftriaxone In Adults With an Ileostomy |
| NCT02563106 | phase2 | completed | 2015-10-01 | 2016-11-01 | Theriva Biologics, Inc. | A Study of SYN-004 for the Prevention of C.Diff in Patients With a LRTI |
| NCT04692181 | phase1_2 | active_not_recruiting | 2021-02-15 | 2029-09-30 | Theriva Biologics, Inc. | SYN-004 Safety and Tolerability in Allo-HCT Subjects |
FDA applications (0)
This company has no applications containing this asset.